Real-world experience with filgotinib for rheumatoid arthritis in Germany
Rattachement africain : de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Real-world data for filgotinib, a Janus kinase (JAK)1 inhibitor, are limited in patients with rheumatoid arthritis (RA). OBJECTIVES: To explore real-world filgotinib use in patients with RA in Germany. MATERIALS AND METHODS: This retrospective chart review included patients aged ≥ 18 years with confirmed moderate to severe RA who initiated filgotinib before December 1, 2021, with ≥ 6 months of medical records available prior to filgotinib initiation or after initial diagnosis. Patient characteristics, prior treatments, reasons for initiating/discontinuing filgotinib, disease activity, dose adjustments and concomitant treatments were recorded. RESULTS: In total, 301 patients from 20 German rheumatology outpatient units were included. One-third were aged ≥ 65 years and almost half had ≥ 1 cardiovascular (CV) risk factor. Most patients initiated filgotinib as monotherapy (83.7%; 12.7% of whom with glucocorticoids) and at the 200 mg dose (84.7%); higher proportions of those initiating the 100 versus 200 mg dose were aged ≥ 65 years and had renal impairment or ≥ 1 CV risk factor. Oral administration (78.4%), fast onset of action (66.8%) and administration as monotherapy (65.4%) were the most common reasons for initiating filgotinib. At 12 months, 41 (18.4%) patients had discontinued filgotinib, most commonly due to lack of effectiveness. After 6‑months of follow-up, 36.8% of patients had achieved Clinical Disease Activity Index (CDAI) remission and 45.6% had achieved CDAI low disease activity. CONCLUSIONS: In clinical practice in Germany, reasons for initiating filgotinib in patients with RA were related to dosing flexibility and general JAK inhibitor attributes. Filgotinib was used predominantly as monotherapy and was effective and generally well tolerated; however, longer-term data in larger, prospective cohorts are needed.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Real-world experience with filgotinib for rheumatoid arthritis in Germany Real-World-Erfahrungen mit Filgotinib bei der Behandlung der rheumatoiden Arthritis in Deutschland
- Date Crossref
- 30/04/2024
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Acura Kliniken pays non établi dans la noticeÉtablissement de santé
-
Helios Hospital Schwerin pays non établi dans la noticeÉtablissement de santé
-
Wismar University of Applied Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Syneos Health (Germany) pays non établi dans la noticeEntreprise
-
St. Bonifatius Hospital pays non établi dans la noticeÉtablissement de santé
-
Praxis for Rheumatology and Clinical Immunology pays non établi dans la noticeÉtablissement de santé
-
Rheumatologische Schwerpunktpraxis Schwerin pays non établi dans la noticeInstitution
-
Ingress-Health HWM GmbH-A Cytel Company pays non établi dans la noticeEntreprise
-
Ingress-Health HWM GmbH—A Cytel Company pays non établi dans la noticeEntreprise
-
Galapagos GmbH pays non établi dans la noticeEntreprise
-
Galapagos Biopharma Germany GmbH pays non établi dans la noticeEntreprise
-
Rheumatologisches Praxiszentrum St. Bonifatius pays non établi dans la noticeInstitution
Acura Kliniken, Helios Hospital Schwerin et Wismar University of Applied Sciences, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.